Precision BioSciences

Baxalta, Precision BioSciences ink $1.6B immuno-oncology collaboration

Friday, February 26, 2016

Baxalta, a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, and Precision BioSciences, a genome editing company, have announced a global collaboration to develop a broad series of allogeneic chimeric antigen receptor (CAR) T cell therapies directed towards areas of major unmet need in multiple cancers.

[Read More]